{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T15:16:20Z","timestamp":1791126980722,"version":"4.1.0"},"reference-count":79,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,1,30]],"date-time":"2023-01-30T00:00:00Z","timestamp":1675036800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,1,30]],"date-time":"2023-01-30T00:00:00Z","timestamp":1675036800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"The Joint Research Committee between St. Olav\u2019s Hospital and Faculty of Medicine and Health Sciences, NTNU"},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["SFB 1444"],"award-info":[{"award-number":["SFB 1444"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["5565-5\/1"],"award-info":[{"award-number":["5565-5\/1"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"name":"The Liaison Committee for education, research, and innovation in Central Norway"},{"name":"NTNU Norwegian University of Science and Technology"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Commun Signal"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>The immunophilin FKBP12 binds to TGF-\u03b2 family type I receptors, including the BMP type I receptor ALK2. FKBP12 keeps the type I receptor in an inactive state and controls signaling activity. Removal of FKBP12 with drugs such as the FKBP-ligand FK506 enhances BMP activity in various cell types. In multiple myeloma cells, activation of SMAD1\/5\/8 leads to apoptosis. We hypothesized that removing FKBP12 from ALK2 in myeloma cells would potentiate BMP-induced ALK2-SMAD1\/5\/8 activity and in consequence cell death.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Multiple myeloma cell lines were treated with FK506, or other FKBP-binding compounds, combined with different BMPs before analyzing SMAD1\/5\/8 activity and cell viability. SMAD1\/5\/8 activity was also investigated using a reporter cell line, INA-6 BRE-luc. To characterize the functional signaling receptor complex, we genetically manipulated receptor expression by siRNA, shRNA and CRISPR\/Cas9 technology.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>FK506 potentiated BMP-induced SMAD1\/5\/8 activation and apoptosis in multiple myeloma cell lines. By using FKBP-binding compounds with different affinity profiles, and siRNA targeting FKBP12, we show that the FK506 effect is mediated by binding to FKBP12. Ligands that typically signal via ALK3 in myeloma cells, BMP2, BMP4, and BMP10, did not induce apoptosis in cells lacking ALK3. Notably, BMP10 competed with BMP6 and BMP9 and antagonized their activity via ALK2. However, upon addition of FK506, we saw a surprising shift in specificity, as the ALK3 ligands gained the ability to signal via ALK2 and induce apoptosis. This indicates that the receptor complex can switch from an inactive non-signaling complex (NSC) to an active one by adding FK506. This gain of activity was also seen in other cell types, indicating that the observed effects have broader relevance. BMP2, BMP4 and BMP10 depended on BMPR2 as type II receptor to signal, which contrasts with BMP6 and BMP9, that activate ALK2 more potently when BMPR2 is knocked down.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>In summary, our data suggest that FKBP12 is a major regulator of ALK2 activity in multiple myeloma cells, partly by switching an NSC into an active signaling complex. FKBP12 targeting compounds devoid of immunosuppressing activity could have potential in novel treatment strategies aiming at reducing multiple myeloma tumor load.<\/jats:p><\/jats:sec>","DOI":"10.1186\/s12964-022-01033-9","type":"journal-article","created":{"date-parts":[[2023,1,30]],"date-time":"2023-01-30T09:04:29Z","timestamp":1675069469000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["FKBP12 is a major regulator of ALK2 activity in multiple myeloma cells"],"prefix":"10.1186","volume":"21","author":[{"given":"Ingrid","family":"Quist-L\u00f8kken","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clara","family":"Andersson-Rusch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin Haugrud","family":"Kastnes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00fcrgen Markus","family":"Kolos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jerome","family":"Jatzlau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanne","family":"Hella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oddrun Elise","family":"Olsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anders","family":"Sundan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petra","family":"Knaus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felix","family":"Hausch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toril","family":"Holien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,1,30]]},"reference":[{"issue":"1","key":"1033_CR1","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/S1359-6101(97)00036-1","volume":"9","author":"M Kawabata","year":"1998","unstructured":"Kawabata M, Imamura T, Miyazono K. Signal transduction by bone morphogenetic proteins. Cytokine Growth Factor Rev. 1998;9(1):49\u201361.","journal-title":"Cytokine Growth Factor Rev"},{"issue":"6","key":"1033_CR2","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1016\/j.tibs.2015.03.012","volume":"40","author":"MJ Macias","year":"2015","unstructured":"Macias MJ, Martin-Malpartida P, Massagu\u00e9 J. Structural determinants of Smad function in TGF-\u03b2 signaling. Trends Biochem Sci. 2015;40(6):296\u2013308.","journal-title":"Trends Biochem Sci"},{"key":"1033_CR3","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.cytogfr.2020.09.003","volume":"57","author":"E Martinez-Hackert","year":"2021","unstructured":"Martinez-Hackert E, Sundan A, Holien T. Receptor binding competition: a paradigm for regulating TGF-\u03b2 family action. Cytokine Growth Factor Rev. 2021;57:39\u201354.","journal-title":"Cytokine Growth Factor Rev"},{"issue":"6","key":"1033_CR4","doi-asserted-by":"publisher","first-page":"1184","DOI":"10.1016\/j.cell.2017.08.015","volume":"170","author":"YE Antebi","year":"2017","unstructured":"Antebi YE, Linton JM, Klumpe H, Bintu B, Gong M, Su C, et al. Combinatorial signal perception in the BMP pathway. Cell. 2017;170(6):1184-1196.e24.","journal-title":"Cell"},{"issue":"13","key":"1033_CR5","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1186\/s12964-015-0104-z","volume":"6","author":"OE Olsen","year":"2015","unstructured":"Olsen OE, Wader KF, Hella H, Mylin AK, Turesson I, Nesthus I, et al. Activin A inhibits BMP-signaling by binding ACVR2A and ACVR2B. Cell Commun Signal. 2015;6(13):27.","journal-title":"Cell Commun Signal"},{"issue":"303","key":"1033_CR6","doi-asserted-by":"publisher","first-page":"303ra137","DOI":"10.1126\/scitranslmed.aac4358","volume":"7","author":"SJ Hatsell","year":"2015","unstructured":"Hatsell SJ, Idone V, Wolken DMA, Huang L, Kim HJ, Wang L, et al. ACVR1R206H receptor mutation causes fibrodysplasia ossificans progressiva by imparting responsiveness to activin A. Sci Transl Med. 2015;7(303):303ra137.","journal-title":"Sci Transl Med."},{"issue":"20","key":"1033_CR7","doi-asserted-by":"publisher","first-page":"10792","DOI":"10.1074\/jbc.M115.713487","volume":"291","author":"S Aykul","year":"2016","unstructured":"Aykul S, Martinez-Hackert E. Transforming growth factor-\u03b2 family ligands can function as antagonists by competing for type II receptor binding. J Biol Chem. 2016;291(20):10792\u2013804.","journal-title":"J Biol Chem"},{"key":"1033_CR8","doi-asserted-by":"publisher","first-page":"e54582","DOI":"10.7554\/eLife.54582","volume":"9","author":"S Aykul","year":"2020","unstructured":"Aykul S, Corpina RA, Goebel EJ, Cunanan CJ, Dimitriou A, Kim HJ, et al. Activin A forms a non-signaling complex with ACVR1 and type II Activin\/BMP receptors via its finger 2 tip loop. Elife. 2020;9:e54582.","journal-title":"Elife"},{"issue":"6244","key":"1033_CR9","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1038\/341758a0","volume":"341","author":"MW Harding","year":"1989","unstructured":"Harding MW, Galat A, Uehling DE, Schreiber SL. A receptor for the immunosuppressant FK506 is a cis-trans peptidyl-prolyl isomerase. Nature. 1989;341(6244):758\u201360.","journal-title":"Nature"},{"issue":"5","key":"1033_CR10","doi-asserted-by":"publisher","first-page":"2425","DOI":"10.1073\/pnas.041614198","volume":"98","author":"B Aghdasi","year":"2001","unstructured":"Aghdasi B, Ye K, Resnick A, Huang A, Ha HC, Guo X, et al. FKBP12, the 12-kDa FK506-binding protein, is a physiologic regulator of the cell cycle. Proc Natl Acad Sci USA. 2001;98(5):2425\u201330.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"9","key":"1033_CR11","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.7164\/antibiotics.40.1249","volume":"40","author":"T Kino","year":"1987","unstructured":"Kino T, Hatanaka H, Hashimoto M, Nishiyama M, Goto T, Okuhara M, et al. FK-506, a novel immunosuppressant isolated from a Streptomyces. I. Fermentation, isolation, and physico-chemical and biological characteristics. J Antibiot (Tokyo). 1987;40(9):1249\u201355.","journal-title":"J Antibiot (Tokyo)"},{"issue":"4","key":"1033_CR12","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1016\/0092-8674(91)90124-H","volume":"66","author":"J Liu","year":"1991","unstructured":"Liu J, Farmer JD, Lane WS, Friedman J, Weissman I, Schreiber SL. Calcineurin is a common target of cyclophilin-cyclosporin A and FKBP-FK506 complexes. Cell. 1991;66(4):807\u201315.","journal-title":"Cell"},{"issue":"6","key":"1033_CR13","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.1016\/j.cell.2012.08.030","volume":"150","author":"S Vilarinho","year":"2012","unstructured":"Vilarinho S, Lifton RP. Liver transplantation: from inception to clinical practice. Cell. 2012;150(6):1096\u20139.","journal-title":"Cell"},{"issue":"22","key":"1033_CR14","doi-asserted-by":"publisher","first-page":"13367","DOI":"10.1074\/jbc.273.22.13367","volume":"273","author":"CB Klee","year":"1998","unstructured":"Klee CB, Ren H, Wang X. Regulation of the Calmodulin-stimulated Protein Phosphatase, Calcineurin *. J Biol Chem. 1998;273(22):13367\u201370.","journal-title":"J Biol Chem"},{"key":"1033_CR15","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.3389\/fphar.2018.01425","volume":"9","author":"JM Kolos","year":"2018","unstructured":"Kolos JM, Voll AM, Bauder M, Hausch F. FKBP ligands-where we are and where to go? Front Pharmacol. 2018;9:1425.","journal-title":"Front Pharmacol"},{"issue":"4991","key":"1033_CR16","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1126\/science.1702904","volume":"251","author":"SL Schreiber","year":"1991","unstructured":"Schreiber SL. Chemistry and biology of the immunophilins and their immunosuppressive ligands. Science. 1991;251(4991):283\u20137.","journal-title":"Science"},{"issue":"6","key":"1033_CR17","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1096\/fasebj.8.6.7513288","volume":"8","author":"DA Fruman","year":"1994","unstructured":"Fruman DA, Burakoff SJ, Bierer BE. Immunophilins in protein folding and immunosuppression. FASEB J. 1994;8(6):391\u2013400.","journal-title":"FASEB J"},{"issue":"5172","key":"1033_CR18","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1126\/science.7518616","volume":"265","author":"T Wang","year":"1994","unstructured":"Wang T, Donahoe PK, Zervos AS. Specific interaction of type I receptors of the TGF-beta family with the immunophilin FKBP-12. Science. 1994;265(5172):674\u20136.","journal-title":"Science"},{"issue":"3","key":"1033_CR19","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1016\/S0092-8674(00)80116-6","volume":"86","author":"T Wang","year":"1996","unstructured":"Wang T, Li BY, Danielson PD, Shah PC, Rockwell S, Lechleider RJ, et al. The immunophilin FKBP12 functions as a common inhibitor of the TGF beta family type I receptors. Cell. 1996;86(3):435\u201344.","journal-title":"Cell"},{"issue":"13","key":"1033_CR20","doi-asserted-by":"publisher","first-page":"3866","DOI":"10.1093\/emboj\/16.13.3866","volume":"16","author":"YG Chen","year":"1997","unstructured":"Chen YG, Liu F, Massague J. Mechanism of TGFbeta receptor inhibition by FKBP12. EMBO J. 1997;16(13):3866\u201376.","journal-title":"EMBO J"},{"issue":"36","key":"1033_CR21","doi-asserted-by":"publisher","first-page":"21687","DOI":"10.1074\/jbc.271.36.21687","volume":"271","author":"T Okadome","year":"1996","unstructured":"Okadome T, Oeda E, Saitoh M, Ichijo H, Moses HL, Miyazono K, et al. Characterization of the interaction of FKBP12 with the transforming growth factor-beta type I receptor in vivo. J Biol Chem. 1996;271(36):21687\u201390.","journal-title":"J Biol Chem"},{"issue":"7","key":"1033_CR22","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1016\/S1074-5521(98)90072-2","volume":"5","author":"BR Stockwell","year":"1998","unstructured":"Stockwell BR, Schreiber SL. TGF-beta-signaling with small molecule FKBP12 antagonists that bind myristoylated FKBP12-TGF-beta type I receptor fusion proteins. Chem Biol. 1998;5(7):385\u201395.","journal-title":"Chem Biol"},{"issue":"9","key":"1033_CR23","doi-asserted-by":"publisher","first-page":"619","DOI":"10.2741\/1095","volume":"1","author":"T Wang","year":"2004","unstructured":"Wang T, Donahoe PK. The immunophilin FKBP12: a molecular guardian of the TGF-beta family type I receptors. Front Biosci. 2004;1(9):619\u201331.","journal-title":"Front Biosci"},{"issue":"2","key":"1033_CR24","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1038\/s41571-020-0427-6","volume":"18","author":"L Mikkilineni","year":"2021","unstructured":"Mikkilineni L, Kochenderfer JN. CAR T cell therapies for patients with multiple myeloma. Nat Rev Clin Oncol. 2021;18(2):71\u201384.","journal-title":"Nat Rev Clin Oncol"},{"issue":"4","key":"1033_CR25","doi-asserted-by":"publisher","first-page":"1565","DOI":"10.1172\/JCI129205","volume":"130","author":"SA Minnie","year":"2020","unstructured":"Minnie SA, Hill GR. Immunotherapy of multiple myeloma. J Clin Invest. 2020;130(4):1565\u201375.","journal-title":"J Clin Invest"},{"issue":"6","key":"1033_CR26","doi-asserted-by":"publisher","first-page":"2005","DOI":"10.1182\/blood.V96.6.2005","volume":"96","author":"C Kawamura","year":"2000","unstructured":"Kawamura C, Kizaki M, Yamato K, Uchida H, Fukuchi Y, Hattori Y, et al. Bone morphogenetic protein-2 induces apoptosis in human myeloma cells with modulation of STAT3. Blood. 2000;96(6):2005\u201311.","journal-title":"Blood"},{"issue":"2","key":"1033_CR27","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1182\/blood.V97.2.516","volume":"97","author":"O Hjertner","year":"2001","unstructured":"Hjertner O, Hjorth-Hansen H, B\u00f6rset M, Seidel C, Waage A, Sundan A. Bone morphogenetic protein-4 inhibits proliferation and induces apoptosis of multiple myeloma cells. Blood. 2001;97(2):516\u201322.","journal-title":"Blood"},{"issue":"17","key":"1033_CR28","doi-asserted-by":"publisher","first-page":"3024","DOI":"10.1038\/sj.onc.1207386","volume":"23","author":"TB Ro","year":"2004","unstructured":"Ro TB, Holt RU, Brenne AT, Hjorth-Hansen H, Waage A, Hjertner O, et al. Bone morphogenetic protein-5, -6 and -7 inhibit growth and induce apoptosis in human myeloma cells. Oncogene. 2004;23(17):3024\u201332.","journal-title":"Oncogene"},{"issue":"5","key":"1033_CR29","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1038\/leu.2011.263","volume":"26","author":"T Holien","year":"2012","unstructured":"Holien T, V\u00e5tsveen TK, Hella H, Rampa C, Brede G, Gr\u00f8seth LAG, et al. Bone morphogenetic proteins induce apoptosis in multiple myeloma cells by Smad-dependent repression of MYC. Leukemia. 2012;26(5):1073\u201380.","journal-title":"Leukemia"},{"issue":"4","key":"1033_CR30","doi-asserted-by":"publisher","first-page":"e196","DOI":"10.1038\/bcj.2014.16","volume":"21","author":"OE Olsen","year":"2014","unstructured":"Olsen OE, Wader KF, Misund K, V\u00e5tsveen TK, R\u00f8 TB, Mylin AK, et al. Bone morphogenetic protein-9 suppresses growth of myeloma cells by signaling through ALK2 but is inhibited by endoglin. Blood Cancer J. 2014;21(4):e196.","journal-title":"Blood Cancer J"},{"issue":"1","key":"1033_CR31","doi-asserted-by":"crossref","first-page":"e10247","DOI":"10.1002\/jbm4.10247","volume":"4","author":"M Westhrin","year":"2019","unstructured":"Westhrin M, Holien T, Zahoor M, Moen SH, Buene G, St\u00f8rdal B, et al. Bone morphogenetic protein 4 gene therapy in mice inhibits myeloma tumor growth, but has a negative impact on bone. JBMR Plus. 2019;4(1):e10247.","journal-title":"JBMR Plus"},{"issue":"1","key":"1033_CR32","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1038\/sj.thj.6200075","volume":"2","author":"R Burger","year":"2001","unstructured":"Burger R, Guenther A, Bakker F, Schmalzing M, Bernand S, Baum W, et al. Gp130 and ras mediated signaling in human plasma cell line INA-6: a cytokine-regulated tumor model for plasmacytoma. Hematol J. 2001;2(1):42\u201353.","journal-title":"Hematol J"},{"issue":"11","key":"1033_CR33","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1002\/gcc.22388","volume":"55","author":"TK V\u00e5tsveen","year":"2016","unstructured":"V\u00e5tsveen TK, B\u00f8rset M, Dikic A, Tian E, Micci F, Lid AHB, et al. VOLIN and KJON\u2014two novel hyperdiploid myeloma cell lines. Genes Chromosomes Cancer. 2016;55(11):890\u2013901.","journal-title":"Genes Chromosomes Cancer"},{"key":"1033_CR34","doi-asserted-by":"crossref","unstructured":"Olsen OE, Sankar M, Elsaadi S, Hella H, Buene G, Darvekar SR, et al. BMPR2 inhibits activin and BMP signaling via wild-type ALK2. J Cell Sci. 2018;131(11):jcs213512.","DOI":"10.1242\/jcs.213512"},{"issue":"5","key":"1033_CR35","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1038\/sj.emboj.7601000","volume":"25","author":"AE Harrington","year":"2006","unstructured":"Harrington AE, Morris-Triggs SA, Ruotolo BT, Robinson CV, Ohnuma SI, Hyv\u00f6nen M. Structural basis for the inhibition of activin signalling by follistatin. EMBO J. 2006;25(5):1035\u201345.","journal-title":"EMBO J"},{"issue":"8","key":"1033_CR36","doi-asserted-by":"publisher","first-page":"3660","DOI":"10.1021\/acs.jmedchem.8b00137","volume":"61","author":"S Pomplun","year":"2018","unstructured":"Pomplun S, Sippel C, H\u00e4hle A, Tay D, Shima K, Klages A, et al. Chemogenomic profiling of human and microbial FK506-binding proteins. J Med Chem. 2018;61(8):3660\u201373.","journal-title":"J Med Chem"},{"issue":"44","key":"1033_CR37","doi-asserted-by":"publisher","first-page":"14758","DOI":"10.1039\/D1SC04638A","volume":"12","author":"JM Kolos","year":"2021","unstructured":"Kolos JM, Pomplun S, Jung S, Rie\u00df B, Purder PL, Voll AM, et al. Picomolar FKBP inhibitors enabled by a single water-displacing methyl group in bicyclic [4.3.1] aza-amides. Chem Sci. 2021;12(44):14758\u201365.","journal-title":"Chem Sci"},{"issue":"7","key":"1033_CR38","doi-asserted-by":"publisher","first-page":"4883","DOI":"10.1074\/jbc.M111023200","volume":"277","author":"O Korchynskyi","year":"2002","unstructured":"Korchynskyi O, ten Dijke P. Identification and functional characterization of distinct critically important bone morphogenetic protein-specific response elements in the Id1 promoter. J Biol Chem. 2002;277(7):4883\u201391.","journal-title":"J Biol Chem"},{"issue":"2","key":"1033_CR39","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1182\/blood-2007-07-101139","volume":"111","author":"UM Fagerli","year":"2008","unstructured":"Fagerli UM, Holt RU, Holien T, Vaatsveen TK, Zhan F, Egeberg KW, et al. Overexpression and involvement in migration by the metastasis-associated phosphatase PRL-3 in human myeloma cells. Blood. 2008;111(2):806\u201315.","journal-title":"Blood"},{"issue":"8","key":"1033_CR40","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1038\/nmeth.3047","volume":"11","author":"NE Sanjana","year":"2014","unstructured":"Sanjana NE, Shalem O, Zhang F. Improved vectors and genome-wide libraries for CRISPR screening. Nat Methods. 2014;11(8):783\u20134.","journal-title":"Nat Methods"},{"issue":"4","key":"1033_CR41","doi-asserted-by":"publisher","first-page":"e62721","DOI":"10.1371\/journal.pone.0062721","volume":"8","author":"CE Sanvitale","year":"2013","unstructured":"Sanvitale CE, Kerr G, Chaikuad A, Ramel MC, Mohedas AH, Reichert S, et al. A new class of small molecule inhibitor of BMP signaling. PLoS ONE. 2013;8(4):e62721.","journal-title":"PLoS ONE"},{"issue":"4","key":"1033_CR42","doi-asserted-by":"publisher","first-page":"E519","DOI":"10.3390\/biom10040519","volume":"10","author":"OE Olsen","year":"2020","unstructured":"Olsen OE, Hella H, Elsaadi S, Jacobi C, Martinez-Hackert E, Holien T. Activins as dual specificity TGF-\u03b2 family molecules: SMAD-activation via activin- and BMP-type 1 receptors. Biomolecules. 2020;10(4):E519.","journal-title":"Biomolecules"},{"issue":"8","key":"1033_CR43","doi-asserted-by":"publisher","first-page":"3600","DOI":"10.1172\/JCI65592","volume":"123","author":"E Spiekerkoetter","year":"2013","unstructured":"Spiekerkoetter E, Tian X, Cai J, Hopper RK, Sudheendra D, Li CG, et al. FK506 activates BMPR2, rescues endothelial dysfunction, and reverses pulmonary hypertension. J Clin Invest. 2013;123(8):3600\u201313.","journal-title":"J Clin Invest"},{"key":"1033_CR44","doi-asserted-by":"crossref","unstructured":"Williams E, Riesebos E, Kerr G, Bullock AN. ALK2 Receptor Kinase Association with FKBP12.6 is structurally conserved with the ALK2-FKBP12 complex. Biomedicines. 2021;9(2):129.","DOI":"10.3390\/biomedicines9020129"},{"issue":"1","key":"1033_CR45","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1038\/nchembio.1699","volume":"11","author":"S Gaali","year":"2015","unstructured":"Gaali S, Kirschner A, Cuboni S, Hartmann J, Kozany C, Balsevich G, et al. Selective inhibitors of the FK506-binding protein 51 by induced fit. Nat Chem Biol. 2015;11(1):33\u20137.","journal-title":"Nat Chem Biol"},{"issue":"8","key":"1033_CR46","doi-asserted-by":"publisher","first-page":"1402","DOI":"10.1002\/cbic.200800806","volume":"10","author":"C Kozany","year":"2009","unstructured":"Kozany C, M\u00e4rz A, Kress C, Hausch F. Fluorescent probes to characterise FK506-binding proteins. ChemBioChem. 2009;10(8):1402\u201310.","journal-title":"ChemBioChem"},{"key":"1033_CR47","doi-asserted-by":"publisher","first-page":"115549","DOI":"10.1016\/j.bone.2020.115549","volume":"140","author":"GR Gipson","year":"2020","unstructured":"Gipson GR, Goebel EJ, Hart KN, Kappes EC, Kattamuri C, McCoy JC, et al. Structural perspective of BMP ligands and signaling. Bone. 2020;140:115549.","journal-title":"Bone"},{"issue":"37","key":"1033_CR48","doi-asserted-by":"publisher","first-page":"32122","DOI":"10.1074\/jbc.M504629200","volume":"280","author":"S Mazerbourg","year":"2005","unstructured":"Mazerbourg S, Sangkuhl K, Luo CW, Sudo S, Klein C, Hsueh AJW. Identification of receptors and signaling pathways for orphan bone morphogenetic protein\/growth differentiation factor ligands based on genomic analyses. J Biol Chem. 2005;280(37):32122\u201332.","journal-title":"J Biol Chem"},{"issue":"33","key":"1033_CR49","doi-asserted-by":"publisher","first-page":"13714","DOI":"10.1074\/jbc.M117.778506","volume":"292","author":"CG Mitrofan","year":"2017","unstructured":"Mitrofan CG, Appleby SL, Nash GB, Mallat Z, Chilvers ER, Upton PD, et al. Bone morphogenetic protein 9 (BMP9) and BMP10 enhance tumor necrosis factor-\u03b1-induced monocyte recruitment to the vascular endothelium mainly via activin receptor-like kinase 2. J Biol Chem. 2017;292(33):13714\u201326.","journal-title":"J Biol Chem"},{"issue":"1","key":"1033_CR50","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1124\/mol.62.1.65","volume":"62","author":"GJ Inman","year":"2002","unstructured":"Inman GJ, Nicol\u00e1s FJ, Callahan JF, Harling JD, Gaster LM, Reith AD, et al. SB-431542 is a potent and specific inhibitor of transforming growth factor-beta superfamily type I activin receptor-like kinase (ALK) receptors ALK4, ALK5, and ALK7. Mol Pharmacol. 2002;62(1):65\u201374.","journal-title":"Mol Pharmacol"},{"issue":"9","key":"1033_CR51","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1016\/j.chembiol.2021.04.001","volume":"28","author":"MH Larraufie","year":"2021","unstructured":"Larraufie MH, Gao X, Xia X, Devine PJ, Kallen J, Liu D, et al. Phenotypic screen identifies calcineurin-sparing FK506 analogs as BMP potentiators for treatment of acute kidney injury. Cell Chem Biol. 2021;28(9):1271-1282.e12.","journal-title":"Cell Chem Biol"},{"issue":"1","key":"1033_CR52","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41392-021-00710-4","volume":"7","author":"T Zhong","year":"2022","unstructured":"Zhong T, Sun X, Yu L, Liu Y, Lin X, Rao Y, et al. PROTAC mediated FKBP12 degradation enhances Hepcidin expression via BMP signaling without immunosuppression activity. Signal Transduct Target Ther. 2022;7(1):1\u20134.","journal-title":"Signal Transduct Target Ther"},{"key":"1033_CR53","doi-asserted-by":"crossref","unstructured":"Sangadala S, Devereaux EJ, Presciutti SM, Boden SD, Willet NJ. FK506 Induces ligand-independent activation of the bone morphogenetic protein pathway and osteogenesis. Int J Mol Sci. 2019;20(8):1900.","DOI":"10.3390\/ijms20081900"},{"issue":"5","key":"1033_CR54","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1016\/j.chembiol.2019.01.011","volume":"26","author":"BJ Peiffer","year":"2019","unstructured":"Peiffer BJ, Qi L, Ahmadi AR, Wang Y, Guo Z, Peng H, et al. Activation of BMP signaling by FKBP12 ligands synergizes with inhibition of CXCR4 to accelerate wound healing. Cell Chem Biol. 2019;26(5):652-661.e4.","journal-title":"Cell Chem Biol"},{"issue":"2","key":"1033_CR55","doi-asserted-by":"publisher","first-page":"a031989","DOI":"10.1101\/cshperspect.a031989","volume":"10","author":"MJ Goumans","year":"2018","unstructured":"Goumans MJ, Zwijsen A, Ten Dijke P, Bailly S. Bone morphogenetic proteins in vascular homeostasis and disease. Cold Spring Harb Perspect Biol. 2018;10(2):a031989.","journal-title":"Cold Spring Harb Perspect Biol"},{"issue":"10","key":"1033_CR56","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/1471-2121-10-20","volume":"19","author":"B Herrera","year":"2009","unstructured":"Herrera B, Inman GJ. A rapid and sensitive bioassay for the simultaneous measurement of multiple bone morphogenetic proteins Identification and quantification of BMP4, BMP6 and BMP9 in bovine and human serum. BMC Cell Biol. 2009r;19(10):20.","journal-title":"BMC Cell Biol"},{"issue":"5","key":"1033_CR57","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1016\/j.cels.2022.03.001","volume":"13","author":"CJ Su","year":"2022","unstructured":"Su CJ, Murugan A, Linton JM, Yeluri A, Bois J, Klumpe H, et al. Ligand-receptor promiscuity enables cellular addressing. Cell Syst. 2022;13(5):408-425.e12.","journal-title":"Cell Syst"},{"issue":"5","key":"1033_CR58","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1016\/j.cels.2022.03.002","volume":"13","author":"HE Klumpe","year":"2022","unstructured":"Klumpe HE, Langley MA, Linton JM, Su CJ, Antebi YE, Elowitz MB. The context-dependent, combinatorial logic of BMP signaling. Cell Syst. 2022;13(5):388-407.e10.","journal-title":"Cell Syst"},{"issue":"26","key":"1033_CR59","doi-asserted-by":"publisher","first-page":"24443","DOI":"10.1074\/jbc.M502825200","volume":"280","author":"PB Yu","year":"2005","unstructured":"Yu PB, Beppu H, Kawai N, Li E, Bloch KD. Bone morphogenetic protein (BMP) type II receptor deletion reveals BMP ligand-specific gain of signaling in pulmonary artery smooth muscle cells. J Biol Chem. 2005;280(26):24443\u201350.","journal-title":"J Biol Chem"},{"issue":"7","key":"1033_CR60","doi-asserted-by":"publisher","first-page":"1308","DOI":"10.1242\/jcs.156737","volume":"128","author":"JW Lowery","year":"2015","unstructured":"Lowery JW, Intini G, Gamer L, Lotinun S, Salazar VS, Ote S, et al. Loss of BMPR2 leads to high bone mass due to increased osteoblast activity. J Cell Sci. 2015;128(7):1308\u201315.","journal-title":"J Cell Sci"},{"issue":"11","key":"1033_CR61","doi-asserted-by":"publisher","first-page":"2605","DOI":"10.1161\/ATVBAHA.119.313357","volume":"40","author":"AL Theilmann","year":"2020","unstructured":"Theilmann AL, Hawke LG, Hilton LR, Whitford MKM, Cole DV, Mackeil JL, et al. Endothelial BMPR2 loss drives a proliferative response to BMP (bone morphogenetic protein) 9 via prolonged canonical signaling. Arterioscler Thromb Vasc Biol. 2020;40(11):2605\u201318.","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"12","key":"1033_CR62","doi-asserted-by":"publisher","first-page":"e3000557","DOI":"10.1371\/journal.pbio.3000557","volume":"17","author":"C Hiepen","year":"2019","unstructured":"Hiepen C, Jatzlau J, Hildebrandt S, Kampfrath B, Goktas M, Murgai A, et al. BMPR2 acts as a gatekeeper to protect endothelial cells from increased TGF\u03b2 responses and altered cell mechanics. PLoS Biol. 2019;17(12):e3000557.","journal-title":"PLoS Biol"},{"key":"1033_CR63","doi-asserted-by":"publisher","unstructured":"Jatzlau J, Burdzinski W, Trumpp M, Obendorf L, Ro\u00dfmann K, Ravn K, et al. A versatile Halo- and SNAP-tagged BMP\/TGF\u03b2 receptor library for quantification of cell surface ligand binding. bioRxiv; 2022. https:\/\/doi.org\/10.1101\/2022.03.04.482944.","DOI":"10.1101\/2022.03.04.482944"},{"issue":"1","key":"1033_CR64","doi-asserted-by":"publisher","first-page":"2395","DOI":"10.1038\/s41467-022-30111-2","volume":"13","author":"J Guo","year":"2022","unstructured":"Guo J, Liu B, Thorikay M, Yu M, Li X, Tong Z, et al. Crystal structures of BMPRII extracellular domain in binary and ternary receptor complexes with BMP10. Nat Commun. 2022;13(1):2395.","journal-title":"Nat Commun"},{"issue":"50","key":"1033_CR65","doi-asserted-by":"publisher","first-page":"15438","DOI":"10.1073\/pnas.1510540112","volume":"112","author":"K Hino","year":"2015","unstructured":"Hino K, Ikeya M, Horigome K, Matsumoto Y, Ebise H, Nishio M, et al. Neofunction of ACVR1 in fibrodysplasia ossificans progressiva. Proc Natl Acad Sci USA. 2015;112(50):15438\u201343.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"2","key":"1033_CR66","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1080\/14728222.2017.1275567","volume":"21","author":"C Guignabert","year":"2017","unstructured":"Guignabert C, Bailly S, Humbert M. Restoring BMPRII functions in pulmonary arterial hypertension: opportunities, challenges and limitations. Expert Opin Ther Targets. 2017;21(2):181\u201390.","journal-title":"Expert Opin Ther Targets"},{"issue":"7","key":"1033_CR67","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1038\/nm.3877","volume":"21","author":"L Long","year":"2015","unstructured":"Long L, Ormiston ML, Yang X, Southwood M, Gr\u00e4f S, Machado RD, et al. Selective enhancement of endothelial BMPR-II with BMP9 reverses pulmonary arterial hypertension. Nat Med. 2015;21(7):777\u201385.","journal-title":"Nat Med"},{"issue":"1","key":"1033_CR68","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1002\/dvdy.395","volume":"251","author":"A Desroches-Castan","year":"2022","unstructured":"Desroches-Castan A, Tillet E, Bouvard C, Bailly S. BMP9 and BMP10: two close vascular quiescence partners that stand out. Dev Dyn. 2022;251(1):178\u201397.","journal-title":"Dev Dyn"},{"issue":"1","key":"1033_CR69","doi-asserted-by":"publisher","first-page":"1416","DOI":"10.1038\/s41467-018-03672-4","volume":"9","author":"S Gr\u00e4f","year":"2018","unstructured":"Gr\u00e4f S, Haimel M, Bleda M, Hadinnapola C, Southgate L, Li W, et al. Identification of rare sequence variation underlying heritable pulmonary arterial hypertension. Nat Commun. 2018;9(1):1416.","journal-title":"Nat Commun"},{"key":"1033_CR70","doi-asserted-by":"publisher","first-page":"102076","DOI":"10.1016\/j.jbc.2022.102076","volume":"26","author":"KY Chu","year":"2022","unstructured":"Chu KY, Malik A, Thamilselvan V, Martinez-Hackert E. Type II BMP and Activin receptors BMPR2 and ACVR2A share a conserved mode of growth factor recognition. J Biol Chem. 2022;26:102076.","journal-title":"J Biol Chem"},{"issue":"28","key":"1033_CR71","doi-asserted-by":"publisher","first-page":"10963","DOI":"10.1074\/jbc.RA118.002968","volume":"293","author":"E Tillet","year":"2018","unstructured":"Tillet E, Ouarn\u00e9 M, Desroches-Castan A, Mallet C, Subileau M, Didier R, et al. A heterodimer formed by bone morphogenetic protein 9 (BMP9) and BMP10 provides most BMP biological activity in plasma. J Biol Chem. 2018;293(28):10963\u201374.","journal-title":"J Biol Chem"},{"issue":"4","key":"1033_CR72","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1016\/j.ekir.2022.01.003","volume":"7","author":"C Heybeli","year":"2022","unstructured":"Heybeli C, Bentall AJ, Alexander MP, Amer H, Buadi FK, Dispenzieri A, et al. Kidney transplant outcomes of patients with multiple myeloma. Kidney Int Rep. 2022;7(4):752\u201362.","journal-title":"Kidney Int Rep"},{"issue":"2","key":"1033_CR73","doi-asserted-by":"publisher","first-page":"101","DOI":"10.2165\/00002018-200023020-00002","volume":"23","author":"I Penn","year":"2000","unstructured":"Penn I. Post-transplant malignancy: the role of immunosuppression. Drug Saf. 2000;23(2):101\u201313.","journal-title":"Drug Saf"},{"issue":"6","key":"1033_CR74","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1111\/j.1600-6143.2004.00450.x","volume":"4","author":"BL Kasiske","year":"2004","unstructured":"Kasiske BL, Snyder JJ, Gilbertson DT, Wang C. Cancer after Kidney Transplantation in the United States. Am J Transplant. 2004;4(6):905\u201313.","journal-title":"Am J Transplant"},{"issue":"1","key":"1033_CR75","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1111\/ctr.12482","volume":"29","author":"S Safadi","year":"2015","unstructured":"Safadi S, Dispenzieri A, Amer H, Gertz MA, Rajkumar SV, Hayman SR, et al. Multiple myeloma after kidney transplantation. Clin Transpl. 2015;29(1):76\u201384.","journal-title":"Clin Transpl"},{"issue":"6","key":"1033_CR76","doi-asserted-by":"publisher","first-page":"e0179406","DOI":"10.1371\/journal.pone.0179406","volume":"12","author":"R Kormann","year":"2017","unstructured":"Kormann R, Fran\u00e7ois H, Moles T, Dantal J, Kamar N, Moreau K, et al. Plasma cell neoplasia after kidney transplantation: French cohort series and review of the literature. PLoS ONE. 2017;12(6):e0179406.","journal-title":"PLoS ONE"},{"issue":"6","key":"1033_CR77","doi-asserted-by":"publisher","first-page":"1523","DOI":"10.1111\/ajt.12234","volume":"13","author":"EA Engels","year":"2013","unstructured":"Engels EA, Clarke CA, Pfeiffer RM, Lynch CF, Weisenburger DD, Gibson TM, et al. Plasma cell neoplasms in US solid organ transplant recipients. Am J Transpl. 2013;13(6):1523\u201332.","journal-title":"Am J Transpl"},{"issue":"24","key":"1033_CR78","doi-asserted-by":"publisher","first-page":"13257","DOI":"10.1002\/anie.202017352","volume":"60","author":"AM Voll","year":"2021","unstructured":"Voll AM, Meyners C, Taubert MC, Bajaj T, Heymann T, Merz S, et al. Macrocyclic FKBP51 ligands define a transient binding mode with enhanced selectivity. Angew Chem Int Ed Engl. 2021;60(24):13257\u201363.","journal-title":"Angew Chem Int Ed Engl"},{"issue":"1","key":"1033_CR79","doi-asserted-by":"publisher","first-page":"1711","DOI":"10.1080\/14756366.2019.1667342","volume":"34","author":"G Caminati","year":"2019","unstructured":"Caminati G, Martina MR, Menichetti S, Procacci P. Blocking the FKBP12 induced dendrimeric burst in aberrant aggregation of \u03b1-synuclein by using the ElteN378 synthetic inhibitor. J Enzyme Inhib Med Chem. 2019;34(1):1711\u20135.","journal-title":"J Enzyme Inhib Med Chem"}],"container-title":["Cell Communication and Signaling"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12964-022-01033-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12964-022-01033-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12964-022-01033-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,5]],"date-time":"2023-12-05T20:52:31Z","timestamp":1701809551000},"score":1,"resource":{"primary":{"URL":"https:\/\/biosignaling.biomedcentral.com\/articles\/10.1186\/s12964-022-01033-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,30]]},"references-count":79,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["1033"],"URL":"https:\/\/doi.org\/10.1186\/s12964-022-01033-9","relation":{},"ISSN":["1478-811X"],"issn-type":[{"value":"1478-811X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,30]]},"assertion":[{"value":"24 June 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 December 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 January 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"25"}}